---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-029503"
form_type: "8-K"
ticker: "LFMD"
cik: "0000948320"
company_name: "LifeMD, Inc."
filed_at: "2026-06-22T12:25:56+00:00"
generated_at: "2026-06-22T12:30:11.491487+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LifeMD partners with Halozyme for exclusive telehealth co-marketing of XYOSTED, launching July 2026 in 37 states

## Summary
- LifeMD will be the exclusive telehealth co-marketing partner for XYOSTED (testosterone enanthate) self-pay program.
- Program launches July 2026; initially available in 37 states with a transparent $249/month all-inclusive price.
- LifeMD's affiliated medical group will evaluate patients, and its pharmacy will be the preferred dispensing pharmacy.
- Three-year initial term with automatic renewal; either party can terminate if co-marketing budget missed for two consecutive quarters.
- Companies will jointly invest in consumer education and promotional initiatives to expand awareness of hypogonadism.

## SEC filing metadata
- accession: 0001493152-26-029503
- form_type: 8-K
- ticker: LFMD
- cik: 0000948320
- company_name: LifeMD, Inc.
- filed_at: 2026-06-22T12:25:56+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/948320/000149315226029503/0001493152-26-029503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/948320/000149315226029503/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-029503
- JSON: https://secwatch.observer/filing/0001493152-26-029503.json
- Plain text: https://secwatch.observer/filing/0001493152-26-029503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.